Yu Ling Yu
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Yu, Yu Ling; Siwy, Justyna; An, De Wei; González, Arantxa; Hansen, Tine W.; Latosinska, Agnieszka; Pellicori, Pierpaolo; Ravassa, Susana; Mariottoni, Beatrice; Verdonschot, Job A.J.; Ahmed, Fozia; Petutschnigg, Johannes; Rossignol, Patrick; Heymans, Stephane; Cuthbert, Joe J; Girerd, Nicolas; Clark, Andrew L.; Verhamme, Peter; Nawrot, Tim S; Janssens, Stefan; Cleland, John G.F.; Zannad, Faiez; Diez, Javier; Mischak, Harald; Ferreira, João Pedro; Staessen, Jan A.; Khan, Javed; Cosmi, Franco; Pizard, Anne; Bozec, Erwan; Moreno, María U.; Brunner La Rocca, Hans P.; Hazebroek, Mark; Edelmann, Frank; Pieske, Burkert; Mamas, Mamas A.; McDonald, Ken; Rouet, Philippe; Thijs, L.; Asayama, Kei; Maestre, Gladys E.; López, Begoñia; Latini, Roberto; Grojean, Stephanie; Collier, Tim
Authors
Justyna Siwy
De Wei An
Arantxa González
Tine W. Hansen
Agnieszka Latosinska
Pierpaolo Pellicori
Susana Ravassa
Beatrice Mariottoni
Job A.J. Verdonschot
Fozia Ahmed
Johannes Petutschnigg
Patrick Rossignol
Stephane Heymans
Dr Joe Cuthbert J.Cuthbert@hull.ac.uk
Academic Clinical Lecturer
Nicolas Girerd
Andrew L. Clark
Peter Verhamme
Tim S Nawrot
Stefan Janssens
John G.F. Cleland
Faiez Zannad
Javier Diez
Harald Mischak
João Pedro Ferreira
Jan A. Staessen
Javed Khan
Franco Cosmi
Anne Pizard
Erwan Bozec
María U. Moreno
Hans P. Brunner La Rocca
Mark Hazebroek
Frank Edelmann
Burkert Pieske
Mamas A. Mamas
Ken McDonald
Philippe Rouet
L. Thijs
Kei Asayama
Gladys E. Maestre
Begoñia López
Roberto Latini
Stephanie Grojean
Tim Collier
Abstract
Objective Heart failure (HF) is characterised by collagen deposition. Urinary proteomic profiling (UPP) followed by peptide sequencing identifies parental proteins, for over 70% derived from collagens. This study aimed to refine understanding of the antifibrotic action of spironolactone. Methods In this substudy (n=290) to the Heart'Omics' in Ageing Study trial, patients were randomised to usual therapy combined or not with spironolactone 25-50 mg/day and followed for 9 months. The analysis included 1498 sequenced urinary peptides detectable in ≥30% of patients and carboxyterminal propeptide of procollagen I (PICP) and PICP/carboxyterminal telopeptide of collagen I (CITP) as serum biomarkers of COL1A1 synthesis. After rank normalisation of biomarker distributions, between-group differences in their changes were assessed by multivariable-adjusted mixed model analysis of variance. Correlations between the changes in urinary peptides and in serum PICP and PICP/CITP were compared between groups using Fisher's Z transform. Results Multivariable-adjusted between-group differences in the urinary peptides with error 1 rate correction were limited to 27 collagen fragments, of which 16 were upregulated (7 COL1A1 fragments) on spironolactone and 11 downregulated (4 COL1A1 fragments). Over 9 months of follow-up, spironolactone decreased serum PICP from 81 (IQR 66-95) to 75 (61-90) µg/L and PICP/CITP from 22 (17-28) to 18 (13-26), whereas no changes occurred in the control group, resulting in a difference (spironolactone minus control) expressed in standardised units of -0.321 (95% CI 0.0007). Spironolactone did not affect the correlations between changes in urinary COL1A1 fragments and in PICP or the PICP/CITP ratio. Conclusions Spironolactone decreased serum markers of collagen synthesis and predominantly downregulated urinary collagen-derived peptides, but upregulated others. The interpretation of these opposite UPP trends might be due to shrinking the body-wide pool of collagens, explaining downregulation, while some degree of collagen synthesis must be maintained to sustain vital organ functions, explaining upregulation. Combining urinary and serum fibrosis markers opens new avenues for the understanding of the action of antifibrotic drugs.
Citation
Yu, Y. L., Siwy, J., An, D. W., González, A., Hansen, T. W., Latosinska, A., Pellicori, P., Ravassa, S., Mariottoni, B., Verdonschot, J. A., Ahmed, F., Petutschnigg, J., Rossignol, P., Heymans, S., Cuthbert, J. J., Girerd, N., Clark, A. L., Verhamme, P., Nawrot, T. S., Janssens, S., …Collier, T. (in press). Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart, https://doi.org/10.1136/heartjnl-2023-323796
Journal Article Type | Article |
---|---|
Acceptance Date | Apr 28, 2024 |
Online Publication Date | May 9, 2024 |
Deposit Date | May 22, 2024 |
Publicly Available Date | May 23, 2024 |
Journal | Heart |
Print ISSN | 1355-6037 |
Electronic ISSN | 1468-201X |
Publisher | BMJ Publishing Group |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1136/heartjnl-2023-323796 |
Public URL | https://hull-repository.worktribe.com/output/4672280 |
Files
Published article
(2 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by-nc/4.0
Copyright Statement
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
You might also like
The beginning of wisdom is the definition of terms: counting heart failure hospitalizations
(2024)
Journal Article
Hospital admissions in the last year of life of patients with heart failure
(2024)
Journal Article